Myriad Genetics Q3 revenue beats on volume growth in hereditary cancer testing

Myriad Genetics

03/11/2025 21:15

Overview

Myriad Genetics Q3 2025 revenue declines 4% yr/yr, beats analyst expectations

Adjusted operating income for Q3 beats analyst estimates

Company recently entered into strategic collaboration with SOPHiA GENETICS for liquid biopsy CDx testing

Outlook

Myriad Genetics reaffirms full-year 2025 revenue guidance of $818 mln to $828 mln

Gross margin for 2025 expected between 69.5% and 70.0%

Adjusted EPS for 2025 projected between $(0.02) and $0.02

Result Drivers

HEREDITARY CANCER GROWTH - Hereditary cancer testing revenue and volume grew 3% and 11% yr/yr, respectively

STRATEGIC COLLABORATION - Entered collaboration with SOPHiA GENETICS to develop liquid biopsy CDx testing solution

PHARMACOGENOMICS DECLINE - Revenue impacted by UnitedHealthcare's discontinuation of coverage for GeneSight

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$205.70 mln
$204.89 mln (13 Analysts)
Q3 Adjusted EPS
-$0.00785 (13 Analysts)
Q3 EPS
-$0.29
Q3 Net Income
-$27.40 mln
Q3 Gross Margin
69.90%
Q3 Adjusted Operating Income
Beat
$4.10 mln
$133,130 (8 Analysts)
Q3 Adjusted Operating Expenses
$140 mln
Q3 Operating Expenses
$167.10 mln
Q3 Operating Income
-$23.30 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 8 "hold" and 3 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Myriad Genetics Inc is $6.50, about 23.7% below its October 31 closing price of $8.04

The stock recently traded at 99 times the next 12-month earnings vs. a P/E of 51 three months ago

Press Release: ID:nGNXbqW5TY

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)